Aevi Genomic Medicine, Inc.: 10-K filed 2017-03-09
What Aevi Genomic Medicine, Inc. reported in its annual report filed 2017-03-09 (fiscal FY 2016): 28 published measures, 140 facts as tagged in accession 0001144204-17-013576.
This filing
- Form
- 10-K (annual report)
- Filed
- 2017-03-09
- Fiscal period
- fiscal FY 2016
- Accession
- 0001144204-17-013576 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Aevi Genomic Medicine, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 40,561,000 | USD | |
| At 2015-12-31 | 54,258,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 5,583,000 | USD | |
| At 2015-12-31 | 3,908,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 34,978,000 | USD | |
| At 2015-12-31 | 50,350,000 | USD | |
| At 2014-12-31 | 29,662,000 | USD | |
| At 2013-12-31 | 18,423,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 39,838,000 | USD | |
| At 2015-12-31 | 53,064,000 | USD | |
| At 2014-12-31 | 33,288,000 | USD | |
| At 2013-12-31 | 22,390,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | -8,483,000 | USD | 92 |
| 2016-01-01 to 2016-12-31 | -41,904,000 | USD | 366 |
| 2016-07-01 to 2016-09-30 | -10,570,000 | USD | 92 |
| 2016-04-01 to 2016-06-30 | -11,707,000 | USD | 91 |
| 2016-01-01 to 2016-03-31 | -11,144,000 | USD | 91 |
| 2015-10-01 to 2015-12-31 | -6,463,000 | USD | 92 |
| 2015-01-01 to 2015-12-31 | -37,992,000 | USD | 365 |
| 2015-07-01 to 2015-09-30 | -16,521,000 | USD | 92 |
| 2015-04-01 to 2015-06-30 | -6,086,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | -8,922,000 | USD | 90 |
| 2014-01-01 to 2014-12-31 | -18,433,000 | USD | 365 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-12-31 | 221,000 | USD | 366 |
| 2015-01-01 to 2015-12-31 | 187,000 | USD | 365 |
| 2014-01-01 to 2014-12-31 | 364,000 | USD | 365 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | -180,034,000 | USD | |
| At 2015-12-31 | -138,130,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | 37,100,778 | shares | 92 |
| 2016-01-01 to 2016-12-31 | 35,161,823 | shares | 366 |
| 2016-07-01 to 2016-09-30 | 37,080,789 | shares | 92 |
| 2016-04-01 to 2016-06-30 | 33,469,789 | shares | 91 |
| 2016-01-01 to 2016-03-31 | 32,953,542 | shares | 91 |
| 2015-10-01 to 2015-12-31 | 32,339,001 | shares | 92 |
| 2015-01-01 to 2015-12-31 | 26,783,623 | shares | 365 |
| 2015-07-01 to 2015-09-30 | 24,982,577 | shares | 92 |
| 2015-04-01 to 2015-06-30 | 24,906,823 | shares | 91 |
| 2015-01-01 to 2015-03-31 | 24,843,516 | shares | 90 |
| 2014-01-01 to 2014-12-31 | 19,246,611 | shares | 365 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | 37,100,778 | shares | 92 |
| 2016-01-01 to 2016-12-31 | 35,161,823 | shares | 366 |
| 2016-07-01 to 2016-09-30 | 37,080,789 | shares | 92 |
| 2016-04-01 to 2016-06-30 | 33,469,789 | shares | 91 |
| 2016-01-01 to 2016-03-31 | 32,953,542 | shares | 91 |
| 2015-10-01 to 2015-12-31 | 32,339,001 | shares | 92 |
| 2015-01-01 to 2015-12-31 | 26,846,270 | shares | 365 |
| 2015-07-01 to 2015-09-30 | 24,982,577 | shares | 92 |
| 2015-04-01 to 2015-06-30 | 25,094,763 | shares | 91 |
| 2015-01-01 to 2015-03-31 | 24,843,516 | shares | 90 |
| 2014-01-01 to 2014-12-31 | 19,294,259 | shares | 365 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | -0.23 | USD/shares | 92 |
| 2016-01-01 to 2016-12-31 | 1.19 | USD/shares | 366 |
| 2016-07-01 to 2016-09-30 | -0.29 | USD/shares | 92 |
| 2016-04-01 to 2016-06-30 | -0.35 | USD/shares | 91 |
| 2016-01-01 to 2016-03-31 | -0.34 | USD/shares | 91 |
| 2015-10-01 to 2015-12-31 | -0.2 | USD/shares | 92 |
| 2015-01-01 to 2015-12-31 | 1.42 | USD/shares | 365 |
| 2015-07-01 to 2015-09-30 | -0.66 | USD/shares | 92 |
| 2015-04-01 to 2015-06-30 | -0.24 | USD/shares | 91 |
| 2015-01-01 to 2015-03-31 | -0.36 | USD/shares | 90 |
| 2014-01-01 to 2014-12-31 | 0.96 | USD/shares | 365 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | -0.23 | USD/shares | 92 |
| 2016-01-01 to 2016-12-31 | 1.19 | USD/shares | 366 |
| 2016-07-01 to 2016-09-30 | -0.29 | USD/shares | 92 |
| 2016-04-01 to 2016-06-30 | -0.35 | USD/shares | 91 |
| 2016-01-01 to 2016-03-31 | -0.34 | USD/shares | 91 |
| 2015-10-01 to 2015-12-31 | -0.2 | USD/shares | 92 |
| 2015-01-01 to 2015-12-31 | 1.45 | USD/shares | 365 |
| 2015-07-01 to 2015-09-30 | -0.66 | USD/shares | 92 |
| 2015-04-01 to 2015-06-30 | -0.28 | USD/shares | 91 |
| 2015-01-01 to 2015-03-31 | -0.36 | USD/shares | 90 |
| 2014-01-01 to 2014-12-31 | 1 | USD/shares | 365 |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-12-31 | 16,000 | USD | 366 |
| 2015-01-01 to 2015-12-31 | 17,000 | USD | 365 |
| 2014-01-01 to 2014-12-31 | 12,000 | USD | 365 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 377,000 | USD | |
| At 2015-12-31 | 424,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-12-31 | 6,788,000 | USD | 366 |
| 2015-01-01 to 2015-12-31 | 9,188,000 | USD | 365 |
| 2014-01-01 to 2014-12-31 | 6,202,000 | USD | 365 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | -8,480,000 | USD | 92 |
| 2016-01-01 to 2016-12-31 | -41,879,000 | USD | 366 |
| 2016-07-01 to 2016-09-30 | -10,571,000 | USD | 92 |
| 2016-04-01 to 2016-06-30 | -11,686,000 | USD | 91 |
| 2016-01-01 to 2016-03-31 | -11,142,000 | USD | 91 |
| 2015-10-01 to 2015-12-31 | -6,436,000 | USD | 92 |
| 2015-01-01 to 2015-12-31 | -36,568,000 | USD | 365 |
| 2015-07-01 to 2015-09-30 | -15,367,000 | USD | 92 |
| 2015-04-01 to 2015-06-30 | -6,917,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | -7,848,000 | USD | 90 |
| 2014-01-01 to 2014-12-31 | -18,939,000 | USD | 365 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 40,173,000 | USD | |
| At 2015-12-31 | 53,811,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 5,583,000 | USD | |
| At 2015-12-31 | 3,908,000 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | 5,135,000 | USD | 92 |
| 2016-01-01 to 2016-12-31 | 28,356,000 | USD | 366 |
| 2016-07-01 to 2016-09-30 | 7,529,000 | USD | 92 |
| 2016-04-01 to 2016-06-30 | 8,741,000 | USD | 91 |
| 2016-01-01 to 2016-03-31 | 6,951,000 | USD | 91 |
| 2015-10-01 to 2015-12-31 | 4,314,000 | USD | 92 |
| 2015-01-01 to 2015-12-31 | 15,444,000 | USD | 365 |
| 2015-07-01 to 2015-09-30 | 4,201,000 | USD | 92 |
| 2015-04-01 to 2015-06-30 | 3,028,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 3,901,000 | USD | 90 |
| 2014-01-01 to 2014-12-31 | 8,253,000 | USD | 365 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 37,103,843 | shares | |
| At 2015-12-31 | 32,860,717 | shares |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 1,802,000 | USD | |
| At 2015-12-31 | 1,581,000 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 1,425,000 | USD | |
| At 2015-12-31 | 1,157,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 335,000 | USD | |
| At 2015-12-31 | 747,000 | USD |
Net deferred tax assets
Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 0 | USD | |
| At 2015-12-31 | 0 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-12-31 | -41,888,000 | USD | 366 |
| 2015-01-01 to 2015-12-31 | -37,975,000 | USD | 365 |
| 2014-01-01 to 2014-12-31 | -18,421,000 | USD | 365 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-12-31 | 41,904,000 | USD | 366 |
| 2015-01-01 to 2015-12-31 | 37,992,000 | USD | 365 |
| 2014-01-01 to 2014-12-31 | 18,433,000 | USD | 365 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | 3,345,000 | USD | 92 |
| 2016-01-01 to 2016-12-31 | 13,523,000 | USD | 366 |
| 2016-07-01 to 2016-09-30 | 3,042,000 | USD | 92 |
| 2016-04-01 to 2016-06-30 | 2,945,000 | USD | 91 |
| 2016-01-01 to 2016-03-31 | 4,191,000 | USD | 91 |
| 2015-10-01 to 2015-12-31 | 2,122,000 | USD | 92 |
| 2015-01-01 to 2015-12-31 | 12,954,000 | USD | 365 |
| 2015-07-01 to 2015-09-30 | 2,996,000 | USD | 92 |
| 2015-04-01 to 2015-06-30 | 3,889,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 3,947,000 | USD | 90 |
| 2014-01-01 to 2014-12-31 | 10,686,000 | USD | 365 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-12-31 | 268,000 | USD | 366 |
| 2015-01-01 to 2015-12-31 | 240,000 | USD | 365 |
| 2014-01-01 to 2014-12-31 | 225,000 | USD | 365 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | -3,000 | USD | 92 |
| 2016-07-01 to 2016-09-30 | 14,000 | USD | 92 |
| 2016-04-01 to 2016-06-30 | -18,000 | USD | 91 |
| 2016-01-01 to 2016-03-31 | -2,000 | USD | 91 |
Inspect the source
- Entity
- Aevi Genomic Medicine, Inc. / CIK 0001138776
- Captured
- SEC response SHA-256
16af7d8db7e8763eb25a11447dbdb1790b536242dd21d662c54ec3da77f91124
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001138776.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))